CO2 Solution Announces U.S. Patent Issuance
New patent covers use of carbonic anhydrase enzyme for carbon capture with amine solvents; supports commercialization of low-cost carbon capture systems
TSX-V: CST Outstanding shares: 60,261,136
QUEBEC CITY, June 29 /PRNewswire-FirstCall/ - CO2 Solution Inc. ("CO2 Solution" or the "Company") is pleased to announce it has received a new United States patent, 7,740,689 - An improved CO2 absorption solution. The patent provides for exclusivity in the field of using the enzyme, carbonic anhydrase, or an analog thereof, for the capture of carbon dioxide with amine solvents, including MDEA, or any combination or part thereof in any process and in any enzyme delivery configuration. In particular, MDEA is viewed as a commercially attractive amine to be kinetically accelerated by carbonic anhydrase given its low regeneration energy and low volatility. The Company believes that the patent has significant value, given the broad process exclusivity that it provides.
This patent supports the commercialization of MDEA and other amine solvent enzyme-accelerated carbon capture processes, for which significant technical evaluation results were announced on June 22, 2010. Based on these results, significant capital and operating savings at commercial scale are projected based on the ability of the enzyme technology to dramatically increase the CO2 absorption rate of MDEA.
Commenting on the patent issuance, Sylvie Fradette, Vice-President, Research & Development remarked, "We are very pleased to receive this patent and the significant scope of protection that if affords our technology with key amine solvents. Given the magnitude of the greenhouse gas emissions problem from power plants and other large industries, the opportunity for carbonic anhydrase to enable low-cost carbon capture with solvents is increasingly growing, and this patent further secures CO2 Solution's technology and intellectual property leadership position in the field."
About CO2 Solution
Based in Quebec City, CO2 Solution Inc. has developed a proprietary bio-technological platform for the efficient capture of carbon dioxide (CO2), the most important greenhouse gas (GHG), from power plants and other large stationary sources of emissions. The Company's technology platform exploits the natural power of a bio-catalyst (enzyme), carbonic anhydrase, which functions within humans and other mammals to manage CO2 during respiration. CO2 Solution has successfully adapted the enzyme to function within an industrial environment, and thus has taken advantage of a biomimetic approach to CO2 capture based on millions of years of evolution. The Company is commercializing its technology for coal fired power generation, the oil sands and other CO2-intensive industries where a low-cost capture solution is key to meeting climate change legislation in a cost effective manner.
CO2 Solution's technology platform is protected by several North American and European patents, including the use of carbonic anhydrase for CO2 capture and release in a packed column system. News releases and additional information can be found at www.co2solution.com
Certain statements in this news release may be forward-looking. These statements relate to future events or CO2 Solution's future economic performance and reflect the current assumptions and expectations of management. Certain unknown factors may affect the events, economic performance and results of operation described herein. CO2 Solution undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable law.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE CO2 SOLUTION INC.